Literature DB >> 3437793

Follow-up study of 582 liver cirrhosis patients for 26 years in Japan.

R Tanaka1, T Itoshima, H Nagashima.   

Abstract

A long-term follow-up study of liver cirrhosis (LC) was performed in 582 patients diagnosed by peritoneoscopy and liver biopsy in the 26 years from 1958 to 1984. The etiology of LC consisted of hepatitis B virus (HBV) in 21%, alcoholic in 39% and cryptogenic in 39%. Fifty-nine percent of patients had died. Causes of death were hepatocellular carcinoma (HCC 44%), liver failure (30%), rupture of esophageal varices (14%), gastrointestinal bleeding (4%) and non-liver-related causes (8%). HCC accounted for increasing percentages (68%) since 1980. In all groups classified by the etiology, the causes of death had the same order in incidence. The age of onset of LC increased by 10 years from 42 to 52 years old and the age of death by 15 years from 43 to 58 in the 26-year period. The cumulative survival rate improved over the period. The 50% survival year was 7.9 in total patients, and 7.0, 8.5 and 10.0 in the three periods 1958-64, 1965-74 and 1975-84, respectively. It was 9.5, 6.3 and 9.8 in HBV, alcoholic and cryptogenic, respectively. LC patients survived 40-44% of the life expectancy of the general population in Japan in all age groups. Cox's multiregression life-table method selected three important prognostic factors from 7 parameters: a poor prognosis with a history of heavy alcohol consumption and old age at onset, and a better prognosis with recent onset.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3437793     DOI: 10.1111/j.1600-0676.1987.tb00362.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  8 in total

1.  The risk of postpolypectomy bleeding during colonoscopy in patients with early liver cirrhosis.

Authors:  Jung Won Jeon; Hyun Phil Shin; Joung Il Lee; Kwang Ro Joo; Kwan Mi Pack; Jae Myung Cha; Jae Jun Park; Jun Uk Lim; Kyuseong Lim
Journal:  Surg Endosc       Date:  2012-05-31       Impact factor: 4.584

2.  Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis.

Authors:  L Bolondi; S Sofia; S Siringo; S Gaiani; A Casali; G Zironi; F Piscaglia; L Gramantieri; M Zanetti; M Sherman
Journal:  Gut       Date:  2001-02       Impact factor: 23.059

3.  Safety and efficacy of endoscopic retrograde cholangiopancreatography for common bile duct stones in liver cirrhotic patients.

Authors:  De-Min Li; Jie Zhao; Qiu Zhao; Hua Qin; Bo Wang; Rong-Xiang Li; Min Zhang; Ji-Fen Hu; Min Yang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-08-19

4.  Equal 3-Year Outcomes for Kidney Transplantation Alone in HCV-Positive Patients With Cirrhosis.

Authors:  Afshin Parsikia; Stalin Campos; Kamran Khanmoradi; John Pang; Manjula Balasubramanian; Radi Zaki; Jorge Ortiz
Journal:  Int Surg       Date:  2015-01

5.  Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications.

Authors:  L Benvegnù; M Gios; S Boccato; A Alberti
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

6.  Survival of patients with alcoholic and cryptogenic cirrhosis without liver transplantation: a single center retrospective study.

Authors:  Sudul Mananjala Senanayake; Madunil Anuk Niriella; Sanjaya Kumara Weerasinghe; Anuradhani Kasturiratne; Jerome Praneeth de Alwis; Arjuna Priyadarsin de Silva; Anuradha Supun Dassanayake; Hithanadura Janaka de Silva
Journal:  BMC Res Notes       Date:  2012-12-02

7.  Prediction of liver-related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis.

Authors:  Seung Up Kim; Ji Hoon Lee; Do Young Kim; Sang Hoon Ahn; Kyu Sik Jung; Eun Hee Choi; Young Nyun Park; Kwang-Hyub Han; Chae Yoon Chon; Jun Yong Park
Journal:  PLoS One       Date:  2012-05-04       Impact factor: 3.240

8.  Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease.

Authors:  Bernhard Scheiner; Lisa Steininger; Georg Semmler; Lukas W Unger; Philipp Schwabl; Theresa Bucsics; Rafael Paternostro; Arnulf Ferlitsch; Michael Trauner; Thomas Reiberger; Mattias Mandorfer
Journal:  Liver Int       Date:  2018-09-22       Impact factor: 5.828

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.